Benzinga | Sep 25, 2020 09:02AM EDT

Establishment Labs Finalizes Distribution Agreement With Puregraft LLC

SANTA BARBARA, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ:ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced it has finalized an amendment to its distribution agreement with Puregraft LLC for Puregraft's line of products for autologous adipose tissue harvesting and redistribution. This amended agreement, which now will continue through the end of 2022, modifies the terms of the original distribution agreement that had terminated earlier this year.



"We are pleased to have reached this modified understanding with Puregraft that will enable us to continue offering the most advanced solution for fat grafting as part of our MotivaHybrid(r) procedure, giving women the option of a natural breast augmentation utilizing their own adipose tissue and our innovative Motiva Implants(r)," said chief executive officer Juan Jos? Chac?n-Quir?s.